EUCTR2011-005408-13-IT进行中（未招募）1 期
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject has provided an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved signed Informed Consent and privacy disclosure as per national regulations (e.g., HIPAA Authorization for U.S. sites) prior to any studyrelated procedures (including withdrawal of prohibited medication, if applicable). 2. Subject is male or female =18 years of age. 3. Subject has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) as defined by the World Health Organization (WHO) criteria, as determined by pathology review at the treating institution and has relapsed or is refractory after 1 second line (salvage) regimen or after HSCT (Appendix 8). 4. Subject is positive for FLT3-ITD activating mutation in bone marrow or peripheral blood (>10% allelic ratio as determined by central lab). 5. ECOG performance status of 0 to 2 (Table 4). 6. In the absence of rapidly progressing disease clearly documented by the investigator, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for prior cytotoxic agents or at least 5 half-lives for prior noncytotoxic agents, including immunosuppressive therapy post HSCT. 7. Persistent chronic clinically significant nonhematological toxicities from prior treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, HSCT, or surgery) must be Grade =1. 8. Subject must have adequate renal, hepatic, and coagulation parameters as indicated by the following laboratory values: ? Alkaline phosphatase(ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) =2.5 x institutional upper limit of normal (ULN) ? Total bilirubin =1.5 x institutional ULN ? Serum creatinine =1.5x institutional ULN and glomerular filtration rate (GFR)>30 mL/min (calculated by Cockcroft and Gault formula, Appendix 9). 9. Subject is able to comply with study procedures and follow-up examinations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Previous treatment with AC220. 2.diagnosis of acute promyelocytic leukemia. 3.diagnosis of chronic myelogenous leukemia (CML) in blast crisis. 4.AML or antecedent MDS secondary to prior chemotherapy. 5.HSCT and either of the following: ? Is within 100 days of transplant ? Is still taking immunosuppressive drugs ? Has clinically significant graft-versus-host disease requiring treatment ? Has G>1 persistent nonhematological toxicity related to the transplant. 6.clinically active CNS leukemia. 7. concurrent chemotherapy, immunotherapy, or radiotherapy within 21 days prior to the first dose of AC220, or any ancillary therapy that is considered to be investigational within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug. 8.treatment with concomitant drugs that prolong QT/QTc interval or with strong inhibitors or inducers of cytochrome P450-isozyme3A4 (CYP3A4) with the exception of antibiotics, antifungals, and antivirals that are used as standard of care (See Appendix 1) 9.treatment with anticoagulant therapy. 10.known positive test for HIV, HCV, or HBV surface antigen. 11.major surgery within 4 weeks prior to first dose of AC220. 12.uncontrolled or significant cardiovascular disease (See Protocol) 13.Subject has a pre-existing disorder predisposing the subject to a serious or life-threatening infection. 14. active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection. 15.any of the following laboratory values: ? Serum potassium <4.0 mmol/L despite supplementation, or >5.5 mmol/L. ? Serum magnesium 3 mg/dL (1.23 mmol/L). ? Serum calcium >11.5 mg/dL (2.9 mmol/L) or ionized calcium >1.5 mmol/L. 16.woman of childbearing potential or a male subject with female partner of childbearing potential who is unwilling or unable to use an acceptable contraceptive method to avoid pregnancy for the entire study period and for at least 3 months after the last dose of study drug. 17.female with a positive pregnancy test, pregnant, or breastfeeding. 18.any medical, psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures.
研究者
相似试验
进行中（未招募）
1 期
AC220 in adults with refractory/relapsed Acute Myeloid LeukaemiaAcute Myeloid LeukemiaEUCTR2011-005408-13-GBAmbit BioSciences Corporation76
已完成
1 期
A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)Respiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12618001838202Avalyn Pharma Pty Ltd91
已完成
2 期
A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)NL-OMON50041Avalyn Pharma, Inc.10
已完成
1 期
A Phase I, Randomised, Open Label Study of the Safety, Tolerability and Pharmacokinetics of Single Sublingual or Oral Dose of GDN-1 in Adult Healthy Volunteers.This trial is to assess the tolerability and pharmacokinetics in healthy adult volunteers and does not focus on any particular health condition or problem.Subsequent studies are planned to evaluate efficacy in promoting improved exercise endurance and recovery, reduced muscle damage and soreness post exercise and for its lipid lowering effects in appropriate populations.This trial is to assess the tolerability and pharmacokinetics in healthy adult volunteers and does not focus on any particular health condition or problem.Subsequent studies are planned to evaluate efficacy in promoting improved exercise endurance and recovery, reduced muscle damage and soreness post exercise and for its lipid lowering effects in appropriate populations.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000560594Gordagen Pharmaceuticals Pty Ltd60
已完成
1 期
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Relapsed/Refractory (R/R) Higher Risk Myelodysplastic Syndrome (MDS)JPRN-jRCT1080224851Astellas Pharma Global Development, Inc.43